$167.79+0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 30, 2026
Company outlook: revenue of $844M to $852M for Fiscal year 2026 — up 14.9% on a year earlier
Just reported
From Repligen Corp.'s results release of October 27, 2026; its quarterly report has since been filed.
Actual
$209.3M
+11% y/y
+2.5% q/q
Guided
—
No guide given
Actual
-$0.68
Guided
—
No guide given
Actual
-$29.5M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $209.3M | $188.8M | +10.86% |
| Profit | -$38.4M | $14.9M | -357.74% |
| Profit per share | -$0.68 | $0.26 | -361.54% |
| Free Cash Flow | $38.2M | $43.4M | -12.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Repligen Corp. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Repligen Corp.’s Item 2.02 8-K filed October 27, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.